All In MedTech

Device Trial Radar · NCT04401631

Analytical Validation of the abioSCOPE Device With an IgE Test Panel: Point-of-Care Precision, Sample Type Comparison and Method Correlation

Last checked: Nov 19, 2026Latest source record: Oct 5, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

Withdrawn

Status

Withdrawn

Enrollment

0

Actual

Start

Nov 2020

Primary completion

Nov 2020

Study completion Dec 2020

Sponsor

Lead sponsor
Abionic SANot on our public-company list
Sponsor type
Industry
Collaborators
NAMSA; Johns Hopkins University
First posted
May 26, 2020

More device trials from this sponsor

Design

Study type
Observational
FDA-regulated device
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a multicenter, prospective, observational study to evaluate the analytical performance of the Abionic IgE Multi-Allergen Test Panel on the abioSCOPE® device in a U.S. point-of-care environment within a clinical laboratory operating under a CLIA certificate for tests of moderate complexity. The study will assess point-of-care ('external') precision, sample type comparison and correlation with a reference method (Phadia Laboratory System, ThermoFisher Scientific).

Conditions

  • Allergy
  • Allergic Asthma
  • Allergy to Cats
  • Allergy to House Dust
  • Allergy to Dog Dander (Finding)
  • Allergy Mold
  • Allergy Cockroach

Interventions

  • Blood CollectionDevice

    Between-Run Reproducibility K3-EDTA venous whole blood 3 mL 1 venous draw Operator-to-operator imprecision (abioSCOPE) K3-EDTA capillary whole blood 0.05 mL/draw; 0.15 mL total 3 finger sticks (3 different fingers) Sample type comparison (abioSCOPE) K3-EDTA capillary whole blood, venous serum, venous K3-EDTA plasma 0.35 mL (finger stick), 9 mL of whole blood to get a minimum of 3 mL of serum and 9 mL of whole blood K3-EDTA to get a minimum of 3 mL of plasma 1 finger stick; 1 venous draw into serum tube (9 mL) and 1 venous draw into K3-EDTA plasma tube (9 mL), in total 18 mL Method comparison (abioSCOPE and ImmunoCAP/Phadia) K3-EDTA capillary whole blood, venous K3-EDTA plasma 0.05 mL (finger stick), 9 mL of whole blood to get a minimum of 3 ml of plasma 1 finger stick; 1 venous draw into K3-EDTA plasma tube (9 mL tube)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. POC variance components (in a POL environment):Time frame: Day 1
  2. Sample type comparison:Time frame: Day 1
  3. Method comparisonTime frame: Day 1

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • George Washington University, Washington DC

    Washington D.C., District of Columbia

  • Johns Hopkins University, Baltimore

    Baltimore, Maryland

  • The Bernstein Clinical Research Center Cincinnati

    Cincinnati, Ohio

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.